Enlivex (ENLV) Cash from Investing Activities (2013 - 2025)
Enlivex (ENLV) posted quarterly Cash from Investing Activities of -$9.4 million for Q4 2025, down 379.33% year-over-year from $3.4 million in Q4 2024, and down 345.87% quarter-over-quarter from $3.8 million in Q3 2025.
Enlivex (ENLV) Cash from Investing Activities (2013 - 2025) Analysis & Trends
Enlivex's Cash from Investing Activities history runs 13 years deep, the most recent figure standing at -$9.4 million for Q4 2025.
- In Q4 2025, Cash from Investing Activities fell 379.33% year-over-year to -$9.4 million; the TTM figure through Dec 2025 stood at -$1.3 million (down 114.6% YoY), while the FY2025 annual figure was -$1.3 million, down 114.6% from the prior year.
- Cash from Investing Activities for Q4 2025 stood at -$9.4 million, down from $3.8 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $59.7 million in Q1 2022, with the low at -$59.6 million in Q1 2021.
- The 5-year median for Cash from Investing Activities is $2.3 million (2024), against an average of $294200.0.
- Peak annual rise in Cash from Investing Activities reached 427.65% in 2021, while the deepest fall reached 2822.46% in 2021.
- Enlivex's Cash from Investing Activities stood at -$5.3 million in 2021, then surged by 46.2% to -$2.9 million in 2022, then surged by 243.78% to $4.1 million in 2023, then decreased by 18.79% to $3.4 million in 2024, then tumbled by 379.33% to -$9.4 million in 2025.
- Business Quant data shows ENLV's Cash from Investing Activities at -$9.4 million in Q4 2025, $3.8 million in Q3 2025, and $1.1 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - | -9.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -9.38 Mn |
| Dec 31, 2025 | -9.38 Mn |
| Sep 30, 2025 | 3.82 Mn |
| Sep 30, 2025 | 3.82 Mn |
| Jun 30, 2025 | 1.07 Mn |
| Jun 30, 2025 | 1.07 Mn |
| Mar 31, 2025 | 3.17 Mn |
| Mar 31, 2025 | 3.17 Mn |
| Dec 31, 2024 | 3.36 Mn |
| Dec 31, 2024 | 3.36 Mn |
| Sep 30, 2024 | 1.40 Mn |
| Sep 30, 2024 | 1.40 Mn |
| Jun 30, 2024 | -794,000.00 |
| Jun 30, 2024 | -794,000.00 |
| Mar 31, 2024 | 5.10 Mn |
| Mar 31, 2024 | 5.10 Mn |
| Dec 31, 2023 | 4.14 Mn |
| Dec 31, 2023 | 4.14 Mn |
| Sep 30, 2023 | 3.95 Mn |
| Sep 30, 2023 | 3.95 Mn |